Human Vaccines & Immunotherapeutics · Available online 28 Jul 2026 · In press · DOI 10.1080/21645515.2026.2704277
Ahmed El Hag, Nardine Nabil, Rowan El Masry, Elsayed Elbadawy Awad, Eman Mahmoud Fouda, Moataza Bashir Hamed, Yasser Abou Talib, Amy Law, Diana Mendes, Mohamed Aladdin
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in infants in low- and middle-income countries, and Egypt faces a clinical and economic burden associated with it. This study aimed to estimate the 5 y budget impact of maternal RSV Prefusion F (RSVpreF) vaccination, compared with no vaccination, from the public healthcare payer perspective in Egypt. A deterministic cohort model simulated weekly birth cohorts for five years, assuming a 10% maternal uptake of RSVpreF administered year-round at 24–36 weeks’ gestation. Outcomes included RSV-LRTI cases, healthcare use (hospitalizations, emergency department, and outpatient), and RSV-related deaths among infants, with costs reported both in aggregate and as per-member-per-year (PMPY). Deterministic sensitivity analysis (DSA) varied clinical and economic inputs by ±30%. Without vaccination, 425,421 RSV-LRTI events, 1,173 RSV-related deaths, and EGP 1,652.3 million in medical costs were projected over five years among 9,877,775 live births. With 10% maternal vaccination, 16,784 RSV-LRTI events and 69 deaths were averted, yielding medical cost offsets of EGP 95.0 million. Vaccination costs of EGP 8,578.1 million produced an incremental PMPY of EGP 15.92 (USD 0.3) under list-price assumptions. In DSA (±30%), results were most sensitive to vaccine acquisition price, with other parameters exerting smaller effects, and the conclusions remained unchanged. Conclusively, maternal RSVpreF vaccination can reduce RSV burden in Egypt’s public sector, and at list price, the program results in a net incremental budget of EGP 15.92 (USD 0.3) PMPY; lower public procurement prices would proportionally reduce the net impact while preserving clinical gains.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Hag, A., Nabil, N., Masry, R., et al. (2026). Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2026.2704277